HC Wainwright Issues Optimistic Estimate for Harrow Earnings

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Harrow, Inc. to $0.10, significantly up from the previous estimate of $0.02, while maintaining a "Buy" rating and a price target of $64.00.
• Harrow's stock has seen a recent price increase of 9.6%, currently trading at $40.01, following a quarterly earnings report that exceeded expectations with $0.24 EPS against a consensus estimate of $0.01.
• Institutional investors and hedge funds own 72.76% of Harrow's shares, indicating strong interest from large investors in the company’s growth potential.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Equities researchers at HC Wainwright lifted their Q3 2025 earnings estimates for Harrow in a research report issued to clients and investors on Wednesday, August 13th. HC Wainwright analyst Y. Chen now forecasts that the company will earn $0.10 per share for the quarter, up from their previous forecast of $0.02. HC Wainwright currently has a "Buy" rating and a $64.00 target price on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow's Q4 2025 earnings at $0.25 EPS and FY2026 earnings at $0.93 EPS.

Several other analysts also recently commented on HROW. William Blair started coverage on Harrow in a research note on Tuesday, June 10th. They issued an "outperform" rating for the company. Zacks Research upgraded Harrow from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Cantor Fitzgerald initiated coverage on Harrow in a research note on Friday, July 11th. They issued an "overweight" rating and a $76.00 target price for the company. Finally, BTIG Research raised their price objective on shares of Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $64.67.

Harrow Stock Down 0.2%

Shares of HROW traded down $0.09 during trading hours on Friday, hitting $38.23. The stock had a trading volume of 606,526 shares, compared to its average volume of 483,640. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.62 and a quick ratio of 0.58. The firm has a 50 day simple moving average of $33.34 and a 200-day simple moving average of $28.92. The firm has a market capitalization of $1.41 billion, a P/E ratio of -152.92 and a beta of 0.41. Harrow has a 1-year low of $20.85 and a 1-year high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.23. The business had revenue of $63.74 million for the quarter, compared to analyst estimates of $64.23 million. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. Harrow has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Braidwell LP lifted its position in shares of Harrow by 106.3% during the fourth quarter. Braidwell LP now owns 907,039 shares of the company's stock valued at $30,431,000 after purchasing an additional 467,401 shares in the last quarter. Voya Investment Management LLC raised its position in Harrow by 4,035.5% in the first quarter. Voya Investment Management LLC now owns 381,461 shares of the company's stock worth $10,147,000 after acquiring an additional 372,237 shares during the period. Diametric Capital LP bought a new stake in Harrow in the second quarter worth about $4,748,000. Bank of America Corp DE raised its position in Harrow by 266.8% in the second quarter. Bank of America Corp DE now owns 213,448 shares of the company's stock worth $6,519,000 after acquiring an additional 155,258 shares during the period. Finally, Divisadero Street Capital Management LP bought a new stake in Harrow in the second quarter worth about $4,293,000. 72.76% of the stock is owned by institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.